Venture Life Group (LSE:VLG) has reported a strong trading performance for the twelve months ended 31 December 2025, with revenue from continuing operations increasing by 32% to £35.1 million, equivalent to 11.1% growth on a proforma basis. The uplift was largely driven by higher volumes and continued momentum across the group’s Power Brands portfolio.
Operational and financial highlights
UK sales rose sharply, up 20.7% to £25.7 million, supported by increased advertising and promotional spend. Performance was led by Balance Activ and Earol, while the Health & Her/Him brands delivered a 44% proforma increase, reflecting growing consumer traction. International revenues declined by 8.7%, mainly due to order phasing and temporary disruption with a distributor, an issue the company says has since been resolved.
During the period, Venture Life completed its strategic transition to a pure-play branded consumer healthcare business following the disposal of its CDMO activities. The group is now integrating international management into its UK commercial team, with the aim of building deeper, more strategic global partnerships. It is also stepping up investment in new product development, working alongside Healthea Group, and rolling out a Microsoft Dynamics 365 ERP system to underpin a more data-driven and digital-led operating model.
The balance sheet remains robust, with net cash of £34.4 million at year-end. This financial strength supports an ongoing share buyback programme and provides capacity for selective, earnings-enhancing acquisitions. Management highlighted an active M&A pipeline focused on women’s and men’s health, energy management and hormonal health. The board reiterated confidence in delivering revenue and adjusted EBITDA expectations for the extended 17-month reporting period ending 31 May 2026.
From a market perspective, Venture Life’s outlook is underpinned by supportive technical indicators and positive corporate actions, including share buybacks and insider buying. These factors signal confidence in the company’s strategy, although valuation concerns remain due to a high price-to-earnings ratio and ongoing profitability challenges.
More about Venture Life Group
Venture Life Group is a UK-headquartered international consumer self-care company focused on the development and commercialisation of over-the-counter healthcare products. Its portfolio includes Balance Activ in women’s intimate healthcare, ENT care spray Earol, Lift and Glucogel for energy and glucose management, and the Health & Her range supporting the hormonal lifecycle. Products are sold through pharmacies, health and beauty retailers, grocery channels and e-commerce platforms, both directly in core markets and via international distribution partners.
Leave a Reply